RPTX Projected Dividend Yield
Repare Therapeutics Inc ( NASDAQ : RPTX )Repare Therapeutics is a precision medicine oncology company focused on the development of synthetic lethality (SL)-based therapies to patients with cancer. Using Co.'s SNIPRx platform, Co. is developing its pipeline of SL product candidates, including its primary product candidate, RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ATM gene (ataxia telangiectasia mutated kinase). Co. is also developing an inhibitor of polymerase theta, which is SL with multiple gene deficiencies found in tumors. 20 YEAR PERFORMANCE RESULTS |
RPTX Dividend History Detail RPTX Dividend News RPTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |